Athanasios Magimbi, MD
Pain Medicine · Tracy, CANPI 1851470959
Payments from drug & device makers
Across 643 payments — averaging $15.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
- Scilex Pharmaceuticals Inc.$2K
- Collegium Pharmaceutical, Inc.$1K
- Forte Bio-pharma LLC$636
- AbbVie$635
- Si-bone, Inc.$589
- plus $3K from 27 others
What the payments were for
- Travel & lodging$5626%
- Food & beverage$9,21294%
- Gifts$00%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 102 | $2,020 |
| Scilex Pharmaceuticals Inc. | 128 | $1,622 |
| Collegium Pharmaceutical, Inc. | 151 | $1,416 |
| Forte Bio-pharma LLC | 4 | $636 |
| AbbVie(2 entities) | 40 | $635 |
| Si-bone, Inc. | 5 | $589 |
| Arbor Pharmaceuticals, Inc. | 48 | $518 |
| Boston Scientific | 47 | $493 |
| Abbott | 24 | $424 |
| Biodelivery Sciences International, Inc. | 15 | $181 |
| Pfizer | 19 | $163 |
| Amgen | 6 | $122 |
| Nalu Medical, Inc. | 5 | $113 |
| Tersera Therapeutics LLC | 5 | $96 |
| Biohaven Pharmaceuticals, Inc. | 5 | $80 |
| Vertex | 3 | $75 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $57 |
| Redhill Biopharma Inc. | 4 | $56 |
| Amneal Pharmaceuticals LLC | 3 | $55 |
| Nevro Corp. | 2 | $52 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $42 |
| West Therapeutics Development, LLC | 2 | $38 |
| MDD US Operations, LLC | 2 | $37 |
| Kaleo, Inc. | 2 | $36 |
| Teva Pharmaceuticals USA, Inc. | 2 | $30 |
| AstraZeneca | 2 | $30 |
| Almatica Pharma LLC | 1 | $30 |
| Curonix LLC | 1 | $29 |
| Lilly USA, LLC | 2 | $25 |
| Daiichi Sankyo Inc. | 1 | $25 |
| Medtronic | 1 | $18 |
| Assertio Therapeutics, Inc. | 1 | $17 |
| Ipsen Biopharmaceuticals, Inc | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Prolate$1,289
- Nalocet$596
- IFUSE IMPLANT SYSTEM$484
How this compares
$9,774 in reported general payments places this provider in the 80th percentile of 840 pain medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Xtampza ErOxycodone Myristate | 116 | $92,433 |
| RelistorMethylnaltrexone Bromide | 28 | $59,988 |
| Hysingla ErHydrocodone Bitartrate | 31 | $57,365 |
| Diclofenac Sodium | 153 | $47,709 |
| MovantikNaloxegol Oxalate | 95 | $42,818 |
| OxycontinOxycodone Hcl | 51 | $29,476 |
| Oxycodone Hcl | 1,266 | $29,312 |
| HorizantGabapentin Enacarbil | 26 | $26,147 |
| BelbucaBuprenorphine Hcl | 31 | $25,472 |
| ZtlidoLidocaine | 42 | $23,167 |
| LinzessLinaclotide | 36 | $18,516 |
| Morphine Sulfate ErMorphine Sulfate | 487 | $17,467 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 456 | $15,223 |
| Fentanyl | 129 | $11,018 |
| Tramadol Hcl ErTramadol Hcl | 190 | $11,007 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca | $1,416 | $117,904147 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor | $2,020 | $59,98828 claims |
| Redhill Biopharma Inc.Movantik | $56 | $42,81895 claims |
| Arbor Pharmaceuticals, Inc.Horizant | $518 | $26,14726 claims |
| Scilex Pharmaceuticals Inc.Ztlido | $1,622 | $23,16742 claims |
| AbbVieLinzess | $635 | $18,51636 claims |
| Almatica Pharma LLCGralise | $30 | $6,72311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 840 pain medicine providers in California.
Other pain medicine in Tracy
- Eric GrigsbyNapa$3.2M
- Jason PopeSanta Rosa$2.8M
- Javid GhandehariSanta Monica$2.7M
- Alexander HerselThousand Oaks$2.1M
- Krishnan ChakravarthyTemecula$1.9M
- Kasra AmirdelfanWalnut Creek$1.7M
- Ramana NaiduLarkspur$1.6M
- Foead GeulaStudio City$1.3M
- Xiang QianRedwood City$941K
- Jacqueline WeisbeinNapa$863K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.